A fusion protein of the human P2Y1 receptor and NTPDase1 exhibits functional activities of the native receptor and ectoenzyme and reduced signaling

被引:12
作者
Alvarado-Castillo, C
Lozano-Zarain, P
Mateo, J
Harden, TK [1 ]
Boyer, JL
机构
[1] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA
[2] Inspire Pharmaceut Inc, Durham, NC USA
关键词
D O I
10.1124/mol.62.3.521
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To begin to address the functional interactions between constitutively released nucleotides, ectonucleotidase activity, and P2Y receptor-promoted signaling responses, we engineered the human P2Y(1) receptor in a fusion protein with a member of the ectonucleoside triphosphate diphosphohydrolase family, NTPDase1. Membranes prepared from Chinese hamster ovary (CHO)-K1 cells stably expressing either wild-type NTPDase1 or the P2Y1 receptor-NTPDase1 fusion protein exhibited nucleotide-hydrolytic activities that were over 300-fold greater than activity measured in membranes from empty vector-transfected cells. The molecular ratio for nucleoside triphosphate versus diphosphate hydrolysis was approximately 1: 0.4 for both the wild-type NTPDase1 and P2Y1 -NTPDase1 fusion protein. Stable expression of the P2Y1 -NTPDase1 fusion protein conferred an ADP and 2MeSADP-promoted Ca2+ response to CHO-K1 cells. Moreover, the maximal capacity of the nonhydrolyzable agonist ADPbetaS to stimulate inositol phosphate accumulation was similar, and the EC50 of ADPbetaS was lower in the fusion protein than the wild-type receptor. In contrast, the substantial nucleotide-hydrolyzing activity of the fusion protein resulted in a greater than 50-fold shift to the right of the concentration-effect curve of ADP for activation of phospholipase C compared with the wild-type receptor. Heterologous expression of the P2Y(1) and other P2Y receptors results in marked increases in basal inositol phosphate levels. Given the high nucleotidase activity and apparently normal receptor signaling activity of the P2Y(1) receptor-NTPDase1 fusion protein, we quantitated basal inositol phosphate accumulation in cells stably expressing either the wild-type P2Y(1) receptor or the fusion protein. Although marked elevation of inositol phosphate levels occurred with wild-type P2Y(1) receptor expression, levels in cells expressing the fusion protein were not different from those in wild-type CHO-K1 cells.
引用
收藏
页码:521 / 528
页数:8
相关论文
共 32 条
[1]  
Beigi R., 1999, AM J PHYSIOL, V276, P267
[2]   Molecular cloning and expression of an avian G protein-coupled P2Y receptor [J].
Boyer, JL ;
Waldo, GL ;
Harden, TK .
MOLECULAR PHARMACOLOGY, 1997, 52 (06) :928-934
[3]   Cystic fibrosis transmembrane conductance regulator facilitates ATP release by stimulating a separate ATP release channel for autocrine control of cell volume regulation [J].
Braunstein, GM ;
Roman, RM ;
Clancy, JP ;
Kudlow, BA ;
Taylor, AL ;
Shylonsky, VG ;
Jovov, B ;
Peter, K ;
Jilling, T ;
Ismailov, II ;
Benos, DJ ;
Schwiebert, LM ;
Fitz, JG ;
Schwiebert, EM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (09) :6621-6630
[4]   SIGNAL-TRANSDUCTION VIA P2-PURINERGIC RECEPTORS FOR EXTRACELLULAR ATP AND OTHER NUCLEOTIDES [J].
DUBYAK, GR ;
ELMOATASSIM, C .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (03) :C577-C606
[5]   Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation [J].
Enjyoji, K ;
Sévigny, J ;
Lin, Y ;
Frenette, PS ;
Christie, PD ;
Esch, JSA ;
Imai, M ;
Edelberg, JM ;
Rayburn, H ;
Lech, M ;
Beeler, DL ;
Csizmadia, E ;
Wagner, DD ;
Robson, SC ;
Rosenberg, RD .
NATURE MEDICINE, 1999, 5 (09) :1010-1017
[6]  
FILTZ TM, 1994, MOL PHARMACOL, V46, P8
[7]   PGE2, Ca2+, and cAMP mediate ATP activation of Cl- channels in pigmented ciliary epithelial cells [J].
Fleischhauer, JC ;
Mitchell, CH ;
Peterson-Yantorno, K ;
Coca-Prados, M ;
Civan, MM .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2001, 281 (05) :C1614-C1623
[8]  
Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058
[9]  
HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pa.35.040195.002545
[10]  
HARDEN TK, 1998, P2 NUCLEOTIDE RECEPT, P109